151 related articles for article (PubMed ID: 19193183)
21. Platelet compatibility of PLGA, chitosan and PLGA-chitosan nanoparticles.
Li X; Radomski A; Corrigan OI; Tajber L; De Sousa Menezes F; Endter S; Medina C; Radomski MW
Nanomedicine (Lond); 2009 Oct; 4(7):735-46. PubMed ID: 19839810
[TBL] [Abstract][Full Text] [Related]
22. Drug intercalation in layered double hydroxide clay: application in the development of a nanocomposite film for guided tissue regeneration.
Chakraborti M; Jackson JK; Plackett D; Brunette DM; Burt HM
Int J Pharm; 2011 Sep; 416(1):305-13. PubMed ID: 21708236
[TBL] [Abstract][Full Text] [Related]
23. Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles.
Niu X; Zou W; Liu C; Zhang N; Fu C
Drug Dev Ind Pharm; 2009 Nov; 35(11):1375-83. PubMed ID: 19832638
[TBL] [Abstract][Full Text] [Related]
24. Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging.
Ye F; Barrefelt A; Asem H; Abedi-Valugerdi M; El-Serafi I; Saghafian M; Abu-Salah K; Alrokayan S; Muhammed M; Hassan M
Biomaterials; 2014 Apr; 35(12):3885-94. PubMed ID: 24495486
[TBL] [Abstract][Full Text] [Related]
25. Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design.
Zhou YZ; Alany RG; Chuang V; Wen J
Drug Dev Ind Pharm; 2013 Feb; 39(2):321-30. PubMed ID: 22607101
[TBL] [Abstract][Full Text] [Related]
26. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors.
Parajó Y; d'Angelo I; Horváth A; Vantus T; György K; Welle A; Garcia-Fuentes M; Alonso MJ
Eur J Pharm Sci; 2010 Dec; 41(5):644-9. PubMed ID: 20869438
[TBL] [Abstract][Full Text] [Related]
27. Preparation and characterization novel polymer-coated magnetic nanoparticles as carriers for doxorubicin.
Li F; Sun J; Zhu H; Wen X; Lin C; Shi D
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):58-62. PubMed ID: 21764271
[TBL] [Abstract][Full Text] [Related]
28. Photochemical internalization for pDNA transfection: evaluation of poly(d,l-lactide-co-glycolide) and poly(ethylenimine) nanoparticles.
Gargouri M; Sapin A; Arıca-Yegin B; Merlin JL; Becuwe P; Maincent P
Int J Pharm; 2011 Jan; 403(1-2):276-84. PubMed ID: 21044878
[TBL] [Abstract][Full Text] [Related]
29. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin.
Yin Y; Chen D; Qiao M; Lu Z; Hu H
J Control Release; 2006 Dec; 116(3):337-45. PubMed ID: 17097180
[TBL] [Abstract][Full Text] [Related]
30. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.
Esmaeili F; Hosseini-Nasr M; Rad-Malekshahi M; Samadi N; Atyabi F; Dinarvand R
Nanomedicine; 2007 Jun; 3(2):161-7. PubMed ID: 17468055
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum.
Kohane DS; Tse JY; Yeo Y; Padera R; Shubina M; Langer R
J Biomed Mater Res A; 2006 May; 77(2):351-61. PubMed ID: 16425240
[TBL] [Abstract][Full Text] [Related]
34. Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment.
Westedt U; Kalinowski M; Wittmar M; Merdan T; Unger F; Fuchs J; Schäller S; Bakowsky U; Kissel T
J Control Release; 2007 May; 119(1):41-51. PubMed ID: 17346845
[TBL] [Abstract][Full Text] [Related]
35. Glucosylated polymeric nanoparticles: a sweetened approach against blood compatibility paradox.
Thasneem YM; Sajeesh S; Sharma CP
Colloids Surf B Biointerfaces; 2013 Aug; 108():337-44. PubMed ID: 23563302
[TBL] [Abstract][Full Text] [Related]
36. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Thamake SI; Raut SL; Gryczynski Z; Ranjan AP; Vishwanatha JK
Biomaterials; 2012 Oct; 33(29):7164-73. PubMed ID: 22795543
[TBL] [Abstract][Full Text] [Related]
37. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
Win KY; Feng SS
Biomaterials; 2005 May; 26(15):2713-22. PubMed ID: 15585275
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility.
Weiss B; Schaefer UF; Zapp J; Lamprecht A; Stallmach A; Lehr CM
J Nanosci Nanotechnol; 2006; 6(9-10):3048-56. PubMed ID: 17048517
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticle infiltration to prepare solvent-free controlled drug delivery systems.
Rodríguez-Cruz IM; Domínguez-Delgado CL; Escobar-Chávez JJ; Leyva-Gómez G; Ganem-Quintanar A; Quintanar-Guerrero D
Int J Pharm; 2009 Apr; 371(1-2):177-81. PubMed ID: 19150491
[TBL] [Abstract][Full Text] [Related]
40. Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis.
Pillai RR; Somayaji SN; Rabinovich M; Hudson MC; Gonsalves KE
Biomed Mater; 2008 Sep; 3(3):034114. PubMed ID: 18708713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
